Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Pulmonx Corp

Get SEC filing alerts via email and in your feed for Pulmonx Corp

LUNG

Pulmonx Corp

About Pulmonx Corp

Pulmonx Corporation is a medical technology company specializing in minimally invasive treatments for severe emphysema, a form of COPD. Its core products include the Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, and LungTraX Platform, used to improve lung function and quality of life. The company serves global markets, offering solutions that are safe, effective, and supported by extensive clinical data and regulatory approvals.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Pulmonx Corp

1
1
Pulmonx Corp Pulmonx Corporation Reports $20.6 Million Revenue in Q1 2026, Down 8.7% Year-Over-Year

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Pulmonx Corp Pulmonx Corporation Reports $90.5 Million Revenue with Improved Net Loss in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Pulmonx Corp Pulmonx Corporation Reports 5.5% Revenue Growth to $21.5 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Pulmonx Corp Pulmonx Reports 14.8% Revenue Growth in Q2 2025, Net Loss of $15.2 Million

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Pulmonx Corp Pulmonx Reports $22.5 Million Revenue in Q1 2025, 19.5% Increase Year-Over-Year

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Pulmonx Corp Pulmonx Corporation Reports 15.4% Revenue Growth to $20.4M in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments